Founded in 2025 and based in the United States, Melazyme develops a precision fermentation platform to produce specialty proteins and high-value biomolecules. Its pipeline includes brazzein and fermentation-derived melanin, which the company says can be produced with adjustable functional properties for different applications. Near-term commercial efforts are focused on the cosmetics sector, and Melazyme is already working with commercial partners and engaging with global manufacturers interested in melanin’s UV protection and pigmentation properties. The company is expanding into other high-value molecules where fermentation may offer advantages over conventional chemical processes. The newly raised seed capital is intended to scale the platform, increase production capacity, and support early commercial deployments and partner collaborations across consumer, industrial, and environmental markets.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

May 2026